The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides

Canadian Journal of Microbiology

Volumn 55, Issue 6, 2009, Pages 705-713

  Wu, Wenhui ^a   Weigand, Luise ^a   Mendez, Susana ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

CpG DNA; IL 6; Leishmania; Leishmanization; Vaccination

Indexed keywords

CPG DNA; IL-6; LEISHMANIA; LEISHMANIZATION; VACCINATION;

DENDRIMERS; DNA; GENES; NUCLEIC ACIDS; VACCINES;

CELL MEMBRANES;

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LIVE VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

DNA; FLAGELLATE; HORMONE; IMMUNE RESPONSE; LEISHMANIASIS; LESION; PROTOZOAN; RODENT; VACCINATION; VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; IMMUNE DEFICIENCY; INOCULATION; KNOCKOUT MOUSE; LEISHMANIA MAJOR; LOW DRUG DOSE; LYMPH NODE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SKIN CELL; SKIN DEFECT; SKIN LEISHMANIASIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VACCINATION; WILD TYPE;

ANIMALS; INTERLEUKIN-6; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; PROTOZOAN VACCINES; VACCINATION; VACCINES, ATTENUATED;

LEISHMANIA MAJOR; MUS;

EID: 67749114317     PISSN: 00084166     EISSN: None     Source Type: Journal    
DOI: 10.1139/W09-017     Document Type: Article

References (22)

1. Aseffa, A., Gumy, A., Launois, P., MacDonald, H.R., Louis, J.A., and Tacchini-Cottier, F. 2002. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J. Immunol. 169(6): 3232-3241. PMID:12218142.
2. Desjeux, P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27(5): 305-318. doi:10.1016/j.cimid.2004. 03.004. PMID:15225981.
3. Gabay, C. 2006. Interleukin-6 and chronic inflammation. Arthritis Res. Ther. 8(Suppl 2): S3. doi:10.1186/ar1917. PMID:16899107.
4. Harrington, L.E., Mangan, P.R., and Weaver, C.T. 2006. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18(3): 349-356. doi:10.1016/j.coi.2006.03.017. PMID:16616472.
5. Jones, S.A., Richards, P.J., Scheller, J., and Rose-John, S. 2005. IL-6 transsignaling: the in vivo consequences. J. Interferon Cytokine Res. 25(5): 241-253. doi:10.1089/jir.2005.25.241. PMID: 15871661.
6. Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., et al. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 368(6469): 339-342. doi:10.1038/368339a0. PMID:8127368. (Pubitemid 24104268)
7. Kopf, M., Ramsay, A., Brombacher, F., Baumann, H., Freer, G., Galanos, C., et al. 1995. Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses. Ann. N. Y. Acad. Sci. 762: 308-318. PMID:7545368.
8. Mangan, J.K., Rane, S.G., Kang, A.D., Amanullah, A., Wong, B.C., and Reddy, E.P. 2004. Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood, 103(11): 4093-4101. doi:10.1182/blood-2003-06-2165. PMID:14976041. (Pubitemid 38685349)
9. Mendez, S., Tabbara, K., Belkaid, Y., Bertholet, S., Verthelyi, D., Klinman, D., et al. 2003. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect. Immun. 71(9): 5121-5129. doi:10.1128/IAI.71.9.5121-5129.2003. PMID:12933855.
10. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl 1): 83-88. PMID:8745930.
11. Moskowitz, N.H., Brown, D.R., and Reiner, S.L. 1997. Efficient immunity against Leishmania major in the absence of interleukin-6. Infect. Immun. 65(6): 2448-2450. PMID:9169788.
12. Murray, H.W. 2008. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice. Infect. Immun. 76(9): 4088-4091. doi:10.1128/IAI.00490-08. PMID:18573898.
13. Murray, H.W., Lu, C.M., Mauze, S., Freeman, S., Moreira, A.L., Kaplan, G., and Coffman, R.L. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70(11): 6284-6293. doi:10.1128/IAI.70.11.6284-6293.2002. PMID:12379707.
14. Ruef, C., Budde, K., Lacy, J., Northemann, W., Baumann, M., Sterzel, R.B., and Coleman, D.L. 1990. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int. 38(2): 249-257. doi:10.1038/ki.1990.193. PMID:2402117. (Pubitemid 20324984)
15. Ryffel, B. 1996. Gene knockout mice as investigative tools in pathophysiology. Int. J. Exp. Pathol. 77(4): 125-141. doi:10.1046/j.1365-2613. 1996.d01-215.x. PMID:8943731.
16. Sacks, D., and Noben-Trauth, N. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2(11): 845-858. doi:10.1038/nri933. PMID: 12415308.
17. Spath, G.F., and Beverley, S.M. 2001. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp. Parasitol. 99(2): 97-103. doi:10.1006/expr.2001. 4656. PMID: 11748963.
18. Tabbara, K.S., Peters, N.C., Afrin, F., Mendez, S., Bertholet, S., Belkaid, Y., and Sacks, D.L. 2005. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect. Immun. 73(8): 4714-4722. doi:10.1128/IAI.73.8.4714-4722.2005. PMID:16040984.
19. Titus, R.G., DeKrey, G.K., Morris, R.V., and Soares, M.B. 2001. Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease. Infect. Immun. 69(8): 5189-5192. doi:10.1128/IAI.69.8.5189-5192.2001. PMID:11447205.
20. Uyttenhove, C., Coulie, P.G., and Van Snick, J. 1988. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/ plasmacytoma growth factor. J. Exp. Med. 167(4): 1417-1427. doi:10.1084/jem.167. 4.1417. PMID: 2965738.
21. Uzonna, J.E., Spath, G.F., Beverley, S.M., and Scott, P. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172(6): 3793-3797. PMID:15004184.
22. Wu, W., Weigand, L., Belkaid, Y., and Mendez, S. 2006. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. Eur. J. Immunol. 36(12): 3238-3247. doi:10.1002/eji. 200636472. PMID:17109471.